Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,167,632
  • Shares Outstanding, K 2,365,590
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.73
  • Price/Sales 4.14
  • Price/Cash Flow 18.18
  • Price/Book 2.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.77 +4.66%
on 12/22/17
87.29 -0.76%
on 01/16/18
+1.77 (+2.09%)
since 12/15/17
3-Month
80.60 +7.48%
on 10/27/17
87.29 -0.76%
on 01/16/18
+0.29 (+0.34%)
since 10/17/17
52-Week
69.53 +24.59%
on 01/24/17
87.29 -0.76%
on 01/16/18
+14.64 (+20.34%)
since 01/17/17

Most Recent Stories

More News
Technology Advancements to Conquer the Precision Medicine Market

Chimeric Antigen Receptor (CAR) T Cell therapy prove effective in treating hematological cancers, with close to 90% clinical response rate

NVS : 86.68 (-0.06%)
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?

We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.

AGEN : 3.91 (+3.17%)
MRK : 62.11 (+0.06%)
VRTX : 157.13 (+0.91%)
NVS : 86.68 (-0.06%)
ALKS : 56.06 (-0.90%)
GSK : 38.11 (+0.50%)
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.

PBYI : 91.80 (+1.05%)
NVS : 86.68 (-0.06%)
RHHBY : 30.4000 (-0.91%)
GSK : 38.11 (+0.50%)
Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.

NVS : 86.68 (-0.06%)
EXEL : 27.65 (-6.75%)
ABBV : 103.19 (+0.68%)
AMGN : 186.71 (+0.63%)
Another Large Pharma Implements Berkeley Lights' Beacon® OptoFluidic Platform for Accelerating Antibody Discovery

Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today that Novartis is implementing BLI's Beacon platform to...

NVS : 86.68 (-0.06%)
Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis 2018-2030 Featuring Key Players - Novartis, Gilead Sciences and Juno Therapeutics

The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis " report has been added to ResearchAndMarkets.com's offering.

NVS : 86.68 (-0.06%)
GILD : 80.75 (+0.62%)
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients

Novartis announced today results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara® (ustekinumab) in delivering clear and almost clear skin...

NVS : 86.68 (-0.06%)
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

Novartis International AG / Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...

NVS : 86.68 (-0.06%)
Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

NVS : 86.68 (-0.06%)
EXEL : 27.65 (-6.75%)
PFE : 36.97 (+1.01%)
GSK : 38.11 (+0.50%)
3 Pharma and Biotech Stocks to Watch Out for in 2018

Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

XOMA : 31.92 (+1.14%)
NVS : 86.68 (-0.06%)
ALKS : 56.06 (-0.90%)
BIIB : 340.22 (+0.40%)
EIGR : 8.10 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 87.53
1st Resistance Point 87.13
Last Price 86.68
1st Support Level 86.49
2nd Support Level 86.25

See More

52-Week High 87.29
Last Price 86.68
Fibonacci 61.8% 80.51
Fibonacci 50% 78.41
Fibonacci 38.2% 76.31
52-Week Low 69.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.